EnXnet Signs Letter of Intent with Tac Unit, LLC
TULSA, Okla. –(BUSINESS WIRE)– EnXnet, Inc. (OTCBB: EXNT) is pleased to announce it has entered into a Letter of Intent with Tac Unit, LLC whereby EnXnet acquires all rights, title and interest in and to a new patented technology (U.S. patent issued on January 1, 2011 ) identified as the Thermal Air Control System.
Adherex Reports First Patient Enrolled in Phase 2 Study of Eniluracil in Metastatic Breast Cancer
RESEARCH TRIANGLE PARK, NORTH CAROLINA — (MARKET WIRE) — 04/27/11 — Adherex Technologies Inc. (TSX: AHX)(PINK SHEETS: ADHXF), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil today announced the enrollment of the first patient in the Phase 2 clinical trial for Metastatic Breast Cancer comparing the oral regiment of Eniluracil + 5-Fluorouracil (5-FU) and Leucovorin versus Capecitabine (Xeloda®).
Reach Messaging Developing First of Its Kind Franchise Mobile App Focused on Local Advertising
ASHBURN, Va. , April 27, 2011 (GLOBE NEWSWIRE) — Reach Messaging Inc. , (OTCBB:RCMH), a leading developer of industry specific mobile phone application and platform technology, today announced the Company will be releasing a new “Local Ad Deal” (LAD) franchise application for the iPhone and Droid within the next few weeks. Upon release, the LAD app will be available on the iPhone App Store and the Android Market.
Empire Begins Pre-Production on “Did U Get My Text”
WESTLAKE VILLAGE, Calif. , April 27, 2011 (GLOBE NEWSWIRE) — Empire Film Group, Inc. (Pink Sheets:EFGU) in association with Sweet Irony Productions, Inc. has announced the start of pre-production activities on the feature film “Did U Get My Text”. The film is a contemporary romantic comedy centered around two people who meet and fall in love almost entirely through text messaging.
GeoVax Labs, Inc. Announces First Quarter Financial Results
ATLANTA , April 27, 2011 /PRNewswire/ — GeoVax Labs, Inc. (OTCBB: GOVXD), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, today announced its financial results for the three months ended March 31, 2011.
GeoVax reported a net loss of $606,282 for the three months ended March 31, 2011 , compared to $690,789 for the same period in 2010. Net losses were partially offset by grant revenues of $893,002 and $1,338,560 for each period, respectively, related to the Company’s grant from the National Institutes of Health (NIH) in support of its HIV/AIDS vaccine development activities. As of March 31, 2011 , the Company reported cash balances totaling $541,727 .
Fresh Start Private Updates on Success of Advertisements With Clear Channel Los Angeles Reaching Projected Audience of Over 6 Million Listeners
LOS ANGELES, CA — (MARKET WIRE) — 04/27/11 — Fresh Start Private (OTCBB: CEYY), a leader in the alcohol treatment and rehabilitation industry, provided an update regarding its advertising contracts with Clear Channel Los Angeles (CCLA).
The Company is only three months into a one year campaign that will total $650,000 . To date, the Company has received approximately 90 new patients directly from the campaign, with a projected return of just under $4 million in patient billings.
Kelyniam Engages Pharmexsys to Support Commercial Launch
CANTON, CT — (MARKET WIRE) — 04/27/11 — Kelyniam Global, Inc. (PINKSHEETS: KLYG), an emerging medical device company, announced today that it has engaged Pharmexsys, LLC to support the launch of their recently approved patient specific custom cranial implant. Pharmexsys is a consulting firm that specializes in helping early stage life science companies design and develop the business systems and infrastructure required to manage rapid growth.